HITS
Every round on record, with the sources behind each and the investors on them.
Every round on record, with the sources behind each and the investors on them.
3 sources · checked 2 times, last 3h ago
Developing: it holds up against its sources so far, and firms up as more reporting lands.
Sources 1 and 2 are duplicate reports and agree. Source 3 is unrelated to this company or round.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $13.5M ₩18.3 billion | ~ 2026-09 | not stated | 3 outlets. #10 in Trending |
3 sources · checked 2 times, last 3h ago [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 3 sources Sources 1 and 2 are duplicate reports and agree. Source 3 is unrelated to this company or round. | ||||
HITS says conventional drug discovery takes about 10 years and costs an average of 3 trillion KRW, while the odds of success are only 1 in 9,000, so its AI aims to reduce trial and error, cost, and experiment time. Its latest 18.3-billion-won Series B is funding an AI co-scientist that combines specialized models and research agents, with planned integration with automated laboratory equipment by 2027.
Checked against 10 sources today
| EARLIER ROUNDS FROM COMPANY RESEARCH · DEVELOPING | ||||
| Series A | 55억 원 | 2022-02-17 | Korea Investment Partners | |
Via Alexandria from FullEnrich: type, industry
Also named as backers in company research: Schmidt Inc., Capstone Partners Inc., Kiwoom Investment, Laplace Partners Inc., Company K Partners, STIC Ventures, TIPS project (Ministry of SMEs and Startups)